Sign in
CompletedPhase 3

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Key facts

Who runs it
Epion Therapeutics
Where
Aurora, Austin, Charlotte, Draper, Highland Park, Memphis, Murrieta, Norfolk, North Dartmouth, Omaha, Scottsdale, and Tucson, United StatesSee the 12 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
398 people enrolled
Started
1 Nov 2023
Ended
17 Mar 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment
  • Placebo and sham treatment
Record updated
25 June 2026

Who can take part

Age
8 years to 45 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Diagnosis of keratoconus

Who cannot take part

  • Contraindications or hypersensitivities to any required study medications
  • Certain concomitant ocular conditions
  • Non-keratoconic ectatic disease
  • Minimal corneal thickness < 350 microns
  • Pregnancy or breastfeeding

Where in United States

  • University of ColoradoAurora, United States
  • Dell Laser ConsultantsAustin, United States
  • Providence Eye and Laser SpecialistsCharlotte, United States
  • Hoopes VisionDraper, United States
  • Chicago Cornea ConsultantsHighland Park, United States
  • VRF Eye Specialty GroupMemphis, United States
  • Inland Eye SpecialistsMurrieta, United States
  • Virginia Eye ConsultantsNorfolk, United States
  • Claris Vision LLC Eye Health Vision Centers - DartmouthNorth Dartmouth, United States
  • Truhlsen Eye InstituteOmaha, United States
  • Schwartz Laser Eye CenterScottsdale, United States
  • Catalina Eye CenterTucson, United States

About the trial

What the trial wants to find out

A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

The 2 groups in the trial

  • Active TreatmentTreatment being tested

    Epithelium-on corneal cross-linking

    Treatment: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment

  • Control TreatmentPlacebo, for comparison

    Placebo and sham for epithelium-on corneal cross-linking

    Treatment: Placebo and sham treatment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus (APRICITY-B)
Record updated
25 June 2026